# Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

> **NCT04820179** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Arizona** · enrollment: 30 (actual)

## Conditions studied

- Pancreatic Cancer
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Cabozantinib + Atezolizumab

## Key facts

- **NCT ID:** NCT04820179
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-12
- **Primary completion:** 2026-02-20
- **Final completion:** 2027-01-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04820179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04820179, "Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04820179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*